<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11642197</article-id><article-id pub-id-type="pmcid-ver">PMC11642197.1</article-id><article-id pub-id-type="pmcaid">11642197</article-id><article-id pub-id-type="pmcaiid">11642197</article-id><article-id pub-id-type="pmid">39685534</article-id><article-id pub-id-type="doi">10.3390/jcm13237074</article-id><article-id pub-id-type="publisher-id">jcm-13-07074</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Real-World Clinical Effectiveness and Safety of Antifibrotics in Progressive Pulmonary Fibrosis Associated with Rheumatoid Arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1614-8064</contrib-id><name name-style="western"><surname>Narv&#225;ez</surname><given-names initials="J">Javier</given-names></name><xref rid="af1-jcm-13-07074" ref-type="aff">1</xref><xref rid="c1-jcm-13-07074" ref-type="corresp">*</xref><xref rid="fn1-jcm-13-07074" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-2060-146X</contrib-id><name name-style="western"><surname>Aguilar-Coll</surname><given-names initials="M">Mart&#237;</given-names></name><xref rid="af1-jcm-13-07074" ref-type="aff">1</xref><xref rid="fn1-jcm-13-07074" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vicens-Zygmunt</surname><given-names initials="V">Vanesa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-jcm-13-07074" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1641-0875</contrib-id><name name-style="western"><surname>Alegre</surname><given-names initials="JJ">Juan Jos&#233;</given-names></name><xref rid="af3-jcm-13-07074" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bermudo</surname><given-names initials="G">Guadalupe</given-names></name><xref rid="af2-jcm-13-07074" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Molina-Molina</surname><given-names initials="M">Mar&#237;a</given-names></name><xref rid="af2-jcm-13-07074" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Mori</surname><given-names initials="S">Shunsuke</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-13-07074"><label>1</label>Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Barcelona, Spain; <email>maguilarco@bellvitgehospital.cat</email></aff><aff id="af2-jcm-13-07074"><label>2</label>Interstitial Lung Disease Unit, Department of Pneumology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Barcelona, Spain; <email>vvicens@bellvitgehospital.cat</email> (V.V.-Z.); </aff><aff id="af3-jcm-13-07074"><label>3</label>Department of Rheumatology, Hospital Universitario Dr. Peset, 46017 Valencia, Spain; <email>txantxo@gmail.com</email></aff><author-notes><corresp id="c1-jcm-13-07074"><label>*</label>Correspondence: <email>fjnarvaez@bellvitgehospital.cat</email></corresp><fn id="fn1-jcm-13-07074"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>13</volume><issue>23</issue><issue-id pub-id-type="pmc-issue-id">477040</issue-id><elocation-id>7074</elocation-id><history><date date-type="received"><day>04</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>14</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-18 11:25:33.247"><day>18</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-13-07074.pdf"/><abstract><p><bold>Background/Objectives</bold>: Interstitial lung disease (ILD) is one of the most severe complications of rheumatoid arthritis (RA). Real-world data on antifibrotic treatment are needed. Our objective was to evaluate the real-world effectiveness and tolerability of antifibrotic agents in patients with progressive fibrosing RA-ILD. <bold>Methods:</bold> A longitudinal, retrospective, observational study was conducted on a cohort of RA-ILD patients treated with either nintedanib or pirfenidone. The data collected included pulmonary function test (PFT) results, adverse events (AEs), tolerability, and drug retention. <bold>Results:</bold> Twenty-seven patients were included; 25 (92.5%) initiated nintedanib, while two initiated pirfenidone. The median follow-up duration was 25 months (IQR 7&#8211;27). The mean decline in %pFVC and %pDLCO from ILD diagnosis to the initiation of antifibrotic therapy were &#8722;8.9% and &#8722;14.8%, respectively. After 6 months of treatment, most patients achieved stabilization in PFT: a &#8710;%pFVC of +1.2% (<italic toggle="yes">p</italic> = 0.611 compared with baseline) and a &#8710;%pDLCO of +3.9% (<italic toggle="yes">p</italic> = 0.400). Eighteen patients completed one year of therapy, with a modest improvement in %pFVC (+4.7%; <italic toggle="yes">p</italic> = 0.023) and stabilization in %pDLCO (&#8722;3.8%; <italic toggle="yes">p</italic> = 0.175). This trend persisted among the nine patients who completed 2 years of treatment (%pFVC +7.7%; <italic toggle="yes">p</italic> = 0.037 and %pDLCO &#8722;2.2%; <italic toggle="yes">p</italic> = 0.621). During the follow-up period, 15% of patients died, and 4% underwent lung transplantation. Adverse events occurred in 81% of patients, leading to discontinuation in 18.5% of cases. The most frequent adverse events were gastrointestinal events and hepatitis, leading to a permanent dose reduction of 40% for nintedanib and 14% for pirfenidone. A second antifibrotic agent was prescribed for 18.5% of the patients. At the end of the follow-up period, 63% of the total cohort remained on antifibrotic therapy. <bold>Conclusions:</bold> According to our results, antifibrotic initiation was associated with a modest improvement in the trajectory of %pFVC and stabilization in %pDLCO. The discontinuation rate in our cohort (37%) was higher than that reported in clinical trials but similar to that reported in previously published real-world studies.</p></abstract><kwd-group><kwd>rheumatoid arthritis</kwd><kwd>interstitial lung diseases</kwd><kwd>antifibrotics</kwd><kwd>nintedanib</kwd><kwd>pirfenidone</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-13-07074"><title>1. Introduction</title><p>Interstitial lung disease (ILD) is one of the most common and severe extra-articular manifestations of rheumatoid arthritis (RA) and significantly contributes to both morbidity and mortality [<xref rid="B1-jcm-13-07074" ref-type="bibr">1</xref>,<xref rid="B2-jcm-13-07074" ref-type="bibr">2</xref>,<xref rid="B3-jcm-13-07074" ref-type="bibr">3</xref>,<xref rid="B4-jcm-13-07074" ref-type="bibr">4</xref>,<xref rid="B5-jcm-13-07074" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-07074" ref-type="bibr">6</xref>,<xref rid="B7-jcm-13-07074" ref-type="bibr">7</xref>]. The most prevalent ILD subtypes among RA patients are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). The UIP pattern observed in RA-ILD closely resembles idiopathic pulmonary fibrosis (IPF), and both are associated with a high risk of progressive pulmonary fibrosis (PPF) and increased short-term mortality. Additionally, some RA patients with NSIP-type ILD may also develop progressive fibrosing patterns [<xref rid="B7-jcm-13-07074" ref-type="bibr">7</xref>].</p><p>The clinical trajectory of RA-ILD varies widely. Approximately 55% of RA-ILD patients experience disease progression [<xref rid="B8-jcm-13-07074" ref-type="bibr">8</xref>,<xref rid="B9-jcm-13-07074" ref-type="bibr">9</xref>], with an estimated 40% meeting the criteria for PPF within 5 years of onset, characterized by a rapid decline in lung function, progression to chronic respiratory failure, and an increased risk of premature mortality [<xref rid="B10-jcm-13-07074" ref-type="bibr">10</xref>,<xref rid="B11-jcm-13-07074" ref-type="bibr">11</xref>]. In patients with a fibrosing phenotype, the same profibrotic pathways that lead to pulmonary fibrosis in IPF are activated [<xref rid="B12-jcm-13-07074" ref-type="bibr">12</xref>,<xref rid="B13-jcm-13-07074" ref-type="bibr">13</xref>]. Once these pathways are triggered, they follow an autonomous and self-perpetuating clinical course [<xref rid="B12-jcm-13-07074" ref-type="bibr">12</xref>,<xref rid="B13-jcm-13-07074" ref-type="bibr">13</xref>]. Inhibiting these activated profibrotic pathways with antifibrotic agents, such as nintedanib or pirfenidone, remains the only strategy to slow or potentially stop fibrosis progression.</p><p>Nintedanib has been formally approved by health authorities for the treatment of progressive fibrosing ILD, regardless of its underlying cause, based on the INBUILD trial, which demonstrated a significantly reduced annual rate of forced vital capacity (FVC) decline in these patients [<xref rid="B14-jcm-13-07074" ref-type="bibr">14</xref>]. In a focused evaluation of the INBUILD study comparing the rate of decline in % FVC over 52 weeks among patients with autoimmune-related ILD, no significant differences were observed based on the HRCT pattern. The adjusted difference for the UIP-like fibrotic pattern was 124.2 (95% CI: 31.1 to 217.4), compared to 41.7 (95% CI: &#8722;112.2 to 195.5) for other fibrotic patterns (<italic toggle="yes">p</italic> = 0.37) [<xref rid="B15-jcm-13-07074" ref-type="bibr">15</xref>]. Subanalyses of the 89 patients with RA-ILD in the INBUILD trial revealed similar efficacy to that observed in other causes of PF-ILD [<xref rid="B16-jcm-13-07074" ref-type="bibr">16</xref>].</p><p>Pirfenidone was evaluated in RA-ILD patients in the TRAIL1 trial, a placebo-controlled study with limited statistical power [<xref rid="B17-jcm-13-07074" ref-type="bibr">17</xref>]. Although the primary endpoint (a composite of &#8805;10% decline in percent predicted FVC (%pFVC) or death within one year) was not met, pirfenidone was associated with a significantly slower rate of FVC decline compared to placebo. Post hoc analyses revealed that the effect of pirfenidone on the decline in FVC was more significant in patients with a UIP pattern [<xref rid="B17-jcm-13-07074" ref-type="bibr">17</xref>]. Based on these findings, the 2023 guidelines from the American College of Rheumatology (ACR) and the American College of Chest Physicians (CHEST) for the management of ILD in systemic autoimmune rheumatic diseases conditionally recommend adding pirfenidone as a treatment option for RA-ILD patients with progression despite first-line treatment [<xref rid="B18-jcm-13-07074" ref-type="bibr">18</xref>].</p><p>Although nintedanib and pirfenidone are effective in slowing the progression of ILD, both drugs are associated with adverse events (AEs) that may restrict their use, often resulting in dose adjustments or discontinuation. While clinical trials provide valuable insights, real-world studies are particularly important because they reflect a broader and more representative patient population typically encountered in clinical practice. Clinical trials frequently exclude patients with advanced disease stages or prevalent comorbidities, while real-world studies not only encompass these individuals but also offer the opportunity for extended follow-up periods.</p><p>This study aims to bridge this gap by evaluating the effectiveness and tolerability of antifibrotic therapy in a real-world cohort of patients with RA-ILD PFF.</p></sec><sec sec-type="methods" id="sec2-jcm-13-07074"><title>2. Methods</title><sec id="sec2dot1-jcm-13-07074"><title>2.1. Study Sample</title><p>We conducted a review of medical records and hospital pharmacy-prescribing databases to identify all RA patients who initiated nintedanib or pirfenidone as part of routine clinical care at two tertiary referral hospitals (Bellvitge University Hospital and Dr. Peset University Hospital, Spain). Antifibrotic therapies were prescribed in all cases due to progressive fibrosing RA-associated interstitial lung disease (RA-ILD), and no patients were excluded based on poor outcomes or early death.</p><p>In line with previous studies from our group [<xref rid="B19-jcm-13-07074" ref-type="bibr">19</xref>,<xref rid="B20-jcm-13-07074" ref-type="bibr">20</xref>,<xref rid="B21-jcm-13-07074" ref-type="bibr">21</xref>], progressive ILD was defined by one or more of the following criteria during follow-up: a relative decline of &#8805;10% in the %pFVC or &#8805;15% in the predicted diffusing capacity for carbon monoxide, corrected for hemoglobin (%pDLCO) during follow-up, or a relative decline of 5&#8211;10% in %pFVC accompanied by a reduction of less than 15% in %pDLCO, together with worsening respiratory symptoms and increased fibrosis as assessed by thoracic high-resolution computed tomography (HRCT) [<xref rid="B14-jcm-13-07074" ref-type="bibr">14</xref>,<xref rid="B22-jcm-13-07074" ref-type="bibr">22</xref>]. These changes occurred within 2 years of ILD diagnosis [<xref rid="B14-jcm-13-07074" ref-type="bibr">14</xref>].</p><p>RA was diagnosed according to the ACR 1987 classification criteria [<xref rid="B23-jcm-13-07074" ref-type="bibr">23</xref>] or the ACR/EULAR 2010 criteria [<xref rid="B24-jcm-13-07074" ref-type="bibr">24</xref>], depending on the year of diagnosis. ILD was identified using HRCT of the chest, with experienced thoracic radiologists classifying cases into three main radiologic patterns based on the American Thoracic Society (ATS)/European Respiratory Society (ERS) International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonias [<xref rid="B25-jcm-13-07074" ref-type="bibr">25</xref>]: (1) UIP; (2) NSIP, and (3) other patterns. The final diagnosis of progressive fibrosing RA-ILD was confirmed in all patients through a multidisciplinary approach.</p><p>Patients were managed according to a standardized protocol within a specialized multidisciplinary unit, overseen jointly by a pulmonologist and a rheumatologist. Pre-existing treatments, including glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), immunosuppressants (ISs), and biologic DMARDs (bDMARDs) initially remained unchanged in all patients. However, adjustments to GC dosages were made as needed after the initiation of antifibrotic therapy, at the discretion of the treating physician.</p><p>Pulmonary function tests (PFTs) were conducted every 6 months following the initiation of treatment. All tests were performed in a standardized manner, following the 2002 recommendations of the Spanish Society of Pneumology and Thoracic Surgery [<xref rid="B26-jcm-13-07074" ref-type="bibr">26</xref>]. Both %pFVC and %pDLCO were measured simultaneously for each patient.</p></sec><sec id="sec2dot2-jcm-13-07074"><title>2.2. Clinical Assessments and Outcome Variables</title><p>The effectiveness of antifibrotic therapies was assessed by evaluating changes in %pFVC and %pDLCO before and after treatment initiation. The progression of PFTs was categorized according to the definitions established by the ATS as worsening (a decrease in %pFVC &gt; 10% or %pDLCO &gt; 15%), stabilization (changes in %pFVC &lt; 10% or %pDLCO &lt; 15%), or improvement (an increase in %pFVC &gt; 10% or %pDLCO &gt; 15%) [<xref rid="B27-jcm-13-07074" ref-type="bibr">27</xref>,<xref rid="B28-jcm-13-07074" ref-type="bibr">28</xref>].</p><p>Data regarding antifibrotic therapies included the specific drug used, dosage, duration of follow-up from the first dose, treatment status at the endpoint (continuation or discontinuation), reasons for discontinuation (if applicable), tolerability, and side effect profile. Additional information on lung transplants and deaths (including causes of death) was also collected. The endpoint for follow-up was defined as the date of the last clinic visit, death, or lung transplant. A retrospective analysis of prospectively collected data was performed.</p></sec><sec id="sec2dot3-jcm-13-07074"><title>2.3. Statistical Analysis</title><p>The results are expressed as the mean &#177; standard deviation (SD) or as the median (interquartile range [IQR], 25th&#8211;75th) as appropriate for continuous data, whereas categorical variables are presented as the number of cases and percentages.</p><p>The Kolmogorov&#8211;Smirnov test was employed to determine whether numerical variables followed a normal distribution. Depending on the distribution, numerical variables were compared using either the Student&#8217;s <italic toggle="yes">t</italic>-test or the Mann&#8211;Whitney U test. For categorical variables, the chi-squared test or Fisher&#8217;s exact test was applied, as appropriate.</p><p>Pulmonary function trends were quantified as a percentage change (delta) from the time of diagnosis of RA-ILD to the time of initiation of antifibrotic treatment (T0) and in relation to T0 for all subsequent evaluations after starting therapy. The paired sample t- test was used to compare pre- and post- antifibrotic treatment means of the main outcome efficacy measures evaluated. Statistical significance was defined as <italic toggle="yes">p</italic> &lt; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-jcm-13-07074"><title>3. Results</title><sec id="sec3dot1-jcm-13-07074"><title>3.1. Patient Characteristics</title><p>To date, antifibrotic therapies have been administered to 27 patients with ongoing progressive fibrosing RA-ILD despite prior immunosuppressive treatment. The key baseline characteristics of this cohort are summarized in <xref rid="jcm-13-07074-t001" ref-type="table">Table 1</xref>. The mean age at the start of antifibrotic therapy was 67 &#177; 10 years. At that time, the median duration of RA was 70.5 months (interquartile range [IQR], 25th&#8211;75th percentile: 27.5&#8211;114 months), while the median time since ILD diagnosis was 29 months (IQR: 20&#8211;50 months).</p><p>Anticitrullinated protein antibodies (ACPA) were positive in 81.5% of patients, and rheumatoid factor (RF) in 85%. Radiologically, 21 patients (78%) were classified as having UIP, five (18%) as fibrotic NSIP, and one (4%) as combined pulmonary fibrosis and emphysema (CPFE). A smoking history was reported in 18 patients (67%).</p><p>With respect to antifibrotic treatment, 25 (92.5%) patients initiated therapy with nintedanib, while two started therapy with pirfenidone due to concurrent anticoagulant use. During follow-up, nintedanib was switched to pirfenidone in five patients because of adverse effects; thus, seven (26%) patients received pirfenidone at some point during the follow-up period.</p><p>At the onset of antifibrotic therapy, 10 (37%) patients exhibited moderate to high RA activity according to the DAS28 ESR score (&gt;3.2). The mean %pFVC was 86.6 &#177; 15 (IQR 25th&#8211;75th percentile, 73&#8211;97.1), and the mean %pDLCO was 54.3 &#177; 14.8 (IQR 44&#8211;66). Fourteen (52%) patients presented a decline of &#8805;10% in %pFVC.</p></sec><sec id="sec3dot2-jcm-13-07074"><title>3.2. Treatment Characteristics</title><p>Prior to the initiation of antifibrotic therapy (see <xref rid="jcm-13-07074-t001" ref-type="table">Table 1</xref>), 26 (96%) patients had been treated with GCs, 22 (82%) had received at least one csDMARD or IS, and 20 (74%) had been treated with one or more bDMARDs.</p><p>Previous csDMARDs and IS included leflunomide (LEF) in 18 (67%) patients, methotrexate (MTX) in seven (26%), sulfasalazine in two (8%), and mycophenolate mofetil (MMF) in two (8%). The previous bDMARDs administered were rituximab (RTX) in 10 (37%), abatacept (ABA) in 11 (41%), anti-tumor necrosis factor (TNF) alpha agents in four (15%), and tocilizumab in one (4%).</p><p>All patients received antifibrotic therapy combined with either a bDMARD, a csDMARD/IS, or both: 17 (63%) received a bDMARD plus a csDMARD/IS, 5 (19%) received only a csDMARD/IS, and five (19%) were on bDMARD monotherapy. Additionally, 25 (93%) patients also received GC at a mean dose of 8.3 &#177; 5.4 mg/day (IQR 5&#8211;10).</p><p>The biologic agents initially administered at the start of antifibrotic therapy were ABA in 11 (41%), RTX in 8 (30%), JAK inhibitors (JAKis) in one (4%), and adalimumab in one (4%). During follow-up, ABA was replaced by a JAKi in one patient, and RTX was exchanged with ABA or vice versa in three patients (two initially treated with ABA were switched to RTX, and one initially treated with RTX to ABA). The immunosuppressive treatments used were LEF in 16 patients (59%), MMF in four (15%), and MTX in one (4%).</p><p>Two patients (7.4%) had type 3 pulmonary hypertension confirmed by right heart catheterization and seven patients (26%) required oxygen therapy at the start of antifibrotic therapy. The median follow-up period after initiating antifibrotic agents was 25 months (IQR 7&#8211;27), with a total follow-up of 48.7 patient years.</p></sec><sec id="sec3dot3-jcm-13-07074"><title>3.3. Efficacy Endpoints</title><p>Changes in the primary efficacy outcome measures assessed at 6 months and 1 year following the initiation of antifibrotic therapy are presented in <xref rid="jcm-13-07074-t002" ref-type="table">Table 2</xref> and <xref rid="jcm-13-07074-t003" ref-type="table">Table 3</xref> and illustrated in <xref rid="jcm-13-07074-f001" ref-type="fig">Figure 1</xref>. Across the entire study population, prior to starting therapy, the mean decline in %pFVC and %pDLCO from the time of ILD diagnosis to the initiation of antifibrotic treatment (T0) was &#8722;8.9% (95% CI: 7.81 to 16.02; <italic toggle="yes">p</italic> = 0.0001) and &#8722;14.8% (95% CI: 9.53 to 20.16; <italic toggle="yes">p</italic> = 0.0001), respectively.</p><p>In three patients, antifibrotic therapy was discontinued due to adverse effects before completing 6 months of treatment. In the remaining 24 patients (twenty-one UIP and three non-UIP patterns), a slower decline in PFT parameters was observed after 6 months of therapy (delta: percentage change from baseline): &#8710;%pFVC + 1.2% (95% CI: &#8722;5.67 to 3.41; <italic toggle="yes">p</italic> = 0.611 compared with T0) and &#8710;%pDLCO + 3.9% (95% CI: &#8722;13.51 to 5.63; <italic toggle="yes">p</italic> = 0.400).</p><p>At 1 year of treatment, data were unavailable for nine patients: three had died due to ILD progression, four had discontinued treatment due to adverse effects, and two had not yet completed 12 months of therapy. Among the 18 patients who completed one year of therapy (15 UIP and three NSIP patterns), a modest improvement in %pFVC was observed (&#8710; + 4.7%, 95% CI: &#8722;8.66 to &#8722;0.74; <italic toggle="yes">p</italic> = 0.023), along with a slowing in %pDLCO decline (&#8710; &#8722; 3.8%, 95% CI: &#8722;1.82 to &#8722;9.25; <italic toggle="yes">p</italic> = 0.175).</p><p>Nine of the 24 patients completed 2 years of treatment (seven UIP and two NSIP), maintaining a response in PFTs: &#8710;%pFVC: +7.7% (95% CI: &#8722;16.07 to &#8722;0.66; <italic toggle="yes">p</italic> = 0.037) and &#8710;%pDLCO: &#8722;2.2% (95% CI: &#8722;7.67 to &#8722;12.07; <italic toggle="yes">p</italic> = 0.621).</p><p>A comparison of pre- and post-treatment pulmonary variables revealed that PFT deterioration either slowed or stabilized in approximately three quarters of the patients (<xref rid="jcm-13-07074-t003" ref-type="table">Table 3</xref> and <xref rid="jcm-13-07074-f002" ref-type="fig">Figure 2</xref>). Additionally, prednisone doses were reduced in 10 out of 25 patients (40%) following the initiation of antifibrotic therapy, with a mean reduction of &#8722;5.8 mg/day (SD: 3.5 mg; 95% CI: 7.73 to 15.62; <italic toggle="yes">p</italic> &lt; 0.046). Efficacy comparisons between radiological patterns could not be performed due to the low number of non-UIP patterns.</p></sec><sec id="sec3dot4-jcm-13-07074"><title>3.4. Antifibrotic Tolerability and Retention</title><p>Seventeen patients (63%) continued treatment after a median follow-up period of 25 months (IQR 7&#8211;27) following the initiation of antifibrotic therapy. Among the 10 patients who discontinued treatment, the reasons were death due to ILD progression and infectious complications in four patients (15%), lung transplantation in one patient (4%), and adverse events leading to treatment discontinuation in five patients (18.5%). The retention rate of patients initially treated with nintedanib was 52% (13/25).</p><p>A total of 81.5% (22/27) of patients experienced adverse events (AEs) attributed to antifibrotic treatment. Their frequency and types are detailed in <xref rid="jcm-13-07074-t004" ref-type="table">Table 4</xref>. As expected, the most common events were gastrointestinal events and hepatitis.</p><p>In 48.1% (13/27) of patients, antifibrotic therapy was temporarily suspended (mean number of suspensions: 1.38 &#177; 0.5; range: 1&#8211;2), and in 63% (17/27) of patients, the recommended dosage was temporarily reduced (mean number of dose reductions: 1.53 &#177; 0.5; range: 1&#8211;3).</p><p>The most frequent AEs leading to treatment discontinuation or permanent dose reduction were diarrhea and hepatitis.</p><p>As previously reported, a second antifibrotic agent was prescribed for five (18.5%) patients; all were initially treated with nintedanib and were switched to pirfenidone due to adverse events. Among these five patients, three (60%) remained on pirfenidone after a median follow-up of 13 months.</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-13-07074"><title>4. Discussion</title><p>To date, the effectiveness and tolerability of antifibrotics in RA-ILD have been evaluated in two randomized controlled trials (INBUILD and TRAIL1) [<xref rid="B16-jcm-13-07074" ref-type="bibr">16</xref>,<xref rid="B17-jcm-13-07074" ref-type="bibr">17</xref>], three observational studies [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07074" ref-type="bibr">31</xref>], and several case reports and case series [<xref rid="B32-jcm-13-07074" ref-type="bibr">32</xref>,<xref rid="B33-jcm-13-07074" ref-type="bibr">33</xref>,<xref rid="B34-jcm-13-07074" ref-type="bibr">34</xref>,<xref rid="B35-jcm-13-07074" ref-type="bibr">35</xref>,<xref rid="B36-jcm-13-07074" ref-type="bibr">36</xref>]. Our study is among the few real-world analyses assessing antifibrotic effectiveness and drug retention in RA-ILD patients. Real-world data enable the inclusion of a more diverse patient population, making the findings more reflective of daily clinical practice. Additionally, real-world studies offer valuable insights into long-term safety, especially concerning rare adverse events.</p><p>In both clinical trials (INBUILD with nintedanib and TRAIL1 with pirfenidone), antifibrotic treatment demonstrated only a significant reduction in the rate of FVC decline, without stopping or improving its value [<xref rid="B16-jcm-13-07074" ref-type="bibr">16</xref>,<xref rid="B17-jcm-13-07074" ref-type="bibr">17</xref>]. In contrast, real-world studies appear to demonstrate either stabilization or a modestly improved trajectory in %pFVC [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07074" ref-type="bibr">31</xref>].</p><p>In our cohort, the initiation of antifibrotics was associated with an initial stabilization in %pFVC at 6 months, followed by a gradual, modest improvement (+4.7%; <italic toggle="yes">p</italic> = 0.023) after the first year of therapy, whereas %pDLCO showed a mild, non-significant decline (&#8722;3.8%; <italic toggle="yes">p</italic> = 0.175), indicating stabilization. The discrepancy between our results and those of the clinical trials may be explained by selection bias, as all our patients were worsening prior to starting antifibrotic treatment, which may bias outcomes toward improvement or stabilization after this time point.</p><p>Duarte et al. [<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>] also reported that antifibrotic therapy interrupted the decline in FVC, shifting from a pre-treatment decrease of 300 &#177; 500 mL per year to an improvement of 200 &#177; 400 mL in the year following treatment initiation (<italic toggle="yes">p</italic> = 0.336), whereas %pDLCO continued to decline slightly (3% pre-treatment vs. 2.9% post-treatment, <italic toggle="yes">p</italic> = 0.75). In Juge et al.&#8216;s study, both nintedanib and pirfenidone were associated with a reduced decline in the FVC and DLCO trajectories over 18 months [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>]. This trajectory change was significant for %pFVC (0.3% per year post-initiation compared with 6.2% per year pre-initiation, <italic toggle="yes">p</italic> = 0.03) but not for absolute FVC or DLCO. In Behera&#8217;s study, after 6 months of antifibrotic treatment, the lung function values stabilized, with the %FVC from 62.5 &#177; 20.04 at baseline to 63.2 &#177; 18.2 (<italic toggle="yes">p</italic> = 0.3) and the %DLCO increasing from 70.1 &#177; 15.2 to 72.1 &#177; 12.4 (<italic toggle="yes">p</italic> = 0.15) [<xref rid="B31-jcm-13-07074" ref-type="bibr">31</xref>].</p><p>Recently, Ushio et al. have further demonstrated that nintedanib combined with ISs significantly improves %FVC in patients with connective tissue disease-associated progressive fibrosing ILD, including cases with RA-ILD. Before treatment, the mean monthly decline in FVC was &#8722;0.70%/month. After therapy, this shifted to a mean increase of +0.54%/month (<italic toggle="yes">p</italic> &lt; 0.001), with greater improvements observed in the nintedanib+IS group (+1.71%/month) compared to the nintedanib monotherapy group (+0.34%/month). Additionally, serum KL-6 levels, a biomarker of fibrosis, decreased significantly. The authors concluded that nintedanib improves %FVC in connective tissue disease-associated PF-ILD, with the combination of nintedanib plus ISs proving more effective than nintedanib monotherapy in stabilizing pulmonary function [<xref rid="B32-jcm-13-07074" ref-type="bibr">32</xref>].</p><p>Despite the apparent beneficial effect of antifibrotic therapy, 15% of our patients died, and 4% underwent lung transplantation during the follow-up period. In other observational studies, mortality rates ranged from 22% to 35% [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>], whereas Juge&#8217;s study reported a lung transplant rate of 5% [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>], which closely aligns with our findings. Given the persistently high rates of lung transplant and mortality, it may be worth reconsidering whether antifibrotics are being introduced too late in clinical practice and assessing the potential benefit of initiating them earlier in patients with fibrotic ILD patterns.</p><p>Real-world data confirm the safety of antifibrotic treatments combined with glucocorticoids, csDMARDs/ISs (LEF, MTX, and MMF), with or without biologic agents (particularly ABA and RTX) or JAK inhibitors, without any observed increase in serious infection risk [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07074" ref-type="bibr">31</xref>,<xref rid="B32-jcm-13-07074" ref-type="bibr">32</xref>,<xref rid="B33-jcm-13-07074" ref-type="bibr">33</xref>,<xref rid="B34-jcm-13-07074" ref-type="bibr">34</xref>,<xref rid="B35-jcm-13-07074" ref-type="bibr">35</xref>,<xref rid="B36-jcm-13-07074" ref-type="bibr">36</xref>]. AEs occurred in 81% of our patients, which is higher than the 25% to 55.4% reported in other observational studies [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07074" ref-type="bibr">31</xref>], but lower than the 100% reported in the INBUILD and TRAIL 1 trials [<xref rid="B16-jcm-13-07074" ref-type="bibr">16</xref>,<xref rid="B17-jcm-13-07074" ref-type="bibr">17</xref>]. As in other studies, the most common AEs were gastrointestinal events and hepatitis.</p><p>In our series, adverse events resulted in a permanent dose reduction for 40% of patients on nintedanib and 14% on pirfenidone and led to the discontinuation of antifibrotic therapy in 18.5% of patients (compared with 21.4% of RA-ILD patients treated with nintedanib in the INBUILD trial [<xref rid="B16-jcm-13-07074" ref-type="bibr">16</xref>] and 24% of patients treated with pirfenidone in the TRAIL1 trial [<xref rid="B17-jcm-13-07074" ref-type="bibr">17</xref>]).</p><p>However, owing to this and other factors (such as death from ILD progression and infectious complications, or the need for lung transplantation), the retention rate at the end of the follow-up period was only 63% (52% for nintedanib). The discontinuation rate in our cohort was 37% overall and 48% among those initially treated with nintedanib, which was higher than that reported in clinical trials (INBUILD: 23.8%, TRAIL1: 24%), but similar to that reported in previously published real-world studies (30% to 46%) [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07074" ref-type="bibr">30</xref>].</p><p>Finally, on the basis of our experience with both RA-ILD and systemic sclerosis-associated ILD, switching to pirfenidone may be a successful alternative for patients intolerant to nintedanib. In our series, efficacy comparisons between radiological patterns could not be performed due to the low number of non-UIP patterns. However, in the study by Juge et al. [<xref rid="B29-jcm-13-07074" ref-type="bibr">29</xref>], both nintedanib and pirfenidone demonstrated similar changes in FVCpp trajectory, with no statistically significant differences.</p><p>When interpreting our study&#8217;s results, it is crucial to acknowledge several limitations inherent to its retrospective observational design. These include the small sample size, selection bias (as all patients had experienced ILD worsening prior to initiating antifibrotic therapy), the absence of post-treatment HRCT, the concomitant use of oral GCs, csDMARDs/ISs, and/or biologics in all patients, and the lack of a control group. While the effects on lung progression cannot be definitively attributed solely to antifibrotics, the study specifically included patients with progressive RA-ILD who had not responded to conventional therapies. Furthermore, the baseline regimens of csDMARDs, ISs, and/or biologic agents were maintained without de-escalation throughout the follow-up period after antifibrotic initiation, allowing patients to serve as their own controls. Pre- and post-treatment lung function trends provided compelling evidence of treatment effects attributable to antifibrotic rescue therapy, a conclusion further supported by the use of objective outcome measures, which minimized examiner bias. Nonetheless, we cannot rule out other residual confounders affecting associations between antifibrotics use and outcomes, since no adjusted analysis could be performed due to the small sample size.</p><p>However, our data reflect outcomes from real-world clinical practice in managing refractory cases of this severe complication, with the added strength that our study was conducted independently of corporate sponsorship. Additionally, patients were followed in a structured, protocolized manner with standardized data collection, and the duration of antifibrotic exposure was relatively prolonged.</p><p>In conclusion, our real-world data indicate that antifibrotic therapy stabilizes lung function in most patients with progressive fibrosing RA-ILD. Adverse events are frequent, particularly gastrointestinal events, which impact treatment survival and lead to a nonnegligible rate of permanent dose reduction and treatment discontinuation. Further studies with larger sample sizes are necessary to strengthen these findings, particularly regarding effectiveness analysis, and to better establish the optimal therapeutic window for their use.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.N., M.A.-C. and M.M.-M.; methodology, J.N., M.A.-C. and M.M.-M.; software, J.N.; validation, J.N., M.A.-C., V.V.-Z., J.J.A., G.B. and M.M.-M. formal analysis, J.N. and M.A.-C.; investigation, J.N., M.A.-C., V.V.-Z., J.J.A., G.B. and M.M.-M.; data curation, J.N., M.A.-C., V.V.-Z., J.J.A., G.B. and M.M.-M.; writing&#8212;original draft preparation, J.N.; writing&#8212;review and editing, J.N., M.A.-C., V.V.-Z., J.J.A., G.B. and M.M.-M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was approved by our institutional ethics committee (Clinical Research Ethics Committee of Bellvitge University Hospital-IDIBELL, PR391/23, 12 January 2024). This study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference for Harmonization.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are included in the paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests related to the preparation of this manuscript.</p></notes><ref-list><title>References</title><ref id="B1-jcm-13-07074"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farquhar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vassallo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name></person-group><article-title>Pulmonary Complications of Rheumatoid Arthritis</article-title><source>Semin. Respir. Crit. Care Med.</source><year>2019</year><volume>40</volume><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1055/s-0039-1683995</pub-id><pub-id pub-id-type="pmid">31137060</pub-id></element-citation></ref><ref id="B2-jcm-13-07074"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yunt</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>J.J.</given-names></name></person-group><article-title>Lung disease in rheumatoid arthritis</article-title><source>Rheum. Dis. Clin. North Am.</source><year>2015</year><volume>41</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.rdc.2014.12.004</pub-id><pub-id pub-id-type="pmid">25836639</pub-id><pub-id pub-id-type="pmcid">PMC4415514</pub-id></element-citation></ref><ref id="B3-jcm-13-07074"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spagnolo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Sverzellati</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name></person-group><article-title>The lung in rheumatoid arthritis: Focus on interstitial lung disease</article-title><source>Arthritis Rheumatol.</source><year>2018</year><volume>70</volume><fpage>1544</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1002/art.40574</pub-id><pub-id pub-id-type="pmid">29806092</pub-id></element-citation></ref><ref id="B4-jcm-13-07074"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bongartz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nannini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Medina-Velasquez</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Achenbach</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Crowson</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Vassallo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name></person-group><article-title>Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study</article-title><source>Arthritis Rheum.</source><year>2010</year><volume>62</volume><fpage>1583</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1002/art.27405</pub-id><pub-id pub-id-type="pmid">20155830</pub-id><pub-id pub-id-type="pmcid">PMC4028137</pub-id></element-citation></ref><ref id="B5-jcm-13-07074"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assayag</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lubin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>King</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Collard</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Ryerson</surname><given-names>C.J.</given-names></name></person-group><article-title>Predictors of mortality in rheumatoid arthritis-related interstitial lung disease</article-title><source>Respirology</source><year>2014</year><volume>19</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1111/resp.12234</pub-id><pub-id pub-id-type="pmid">24372981</pub-id></element-citation></ref><ref id="B6-jcm-13-07074"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyldgaard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hilberg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ulrichsen</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>L&#248;kke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bendstrup</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ellingsen</surname><given-names>T.</given-names></name></person-group><article-title>A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: Comorbidity and mortality</article-title><source>Ann. Rheum. Dis.</source><year>2017</year><volume>76</volume><fpage>1700</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2017-211138</pub-id><pub-id pub-id-type="pmid">28611082</pub-id></element-citation></ref><ref id="B7-jcm-13-07074"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koduri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>J.J.</given-names></name></person-group><article-title>Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease</article-title><source>Arthritis Rheumatol.</source><year>2023</year><volume>75</volume><fpage>2067</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1002/art.42640</pub-id><pub-id pub-id-type="pmid">37395725</pub-id></element-citation></ref><ref id="B8-jcm-13-07074"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamora-Legoff</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Crowson</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name></person-group><article-title>Progressive Decline of Lung Function in Rheumatoid Arthritis&#8211;Associated Interstitial Lung Disease</article-title><source>Arthritis Rheumatol.</source><year>2017</year><volume>69</volume><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1002/art.39971</pub-id><pub-id pub-id-type="pmid">27788297</pub-id><pub-id pub-id-type="pmcid">PMC5328843</pub-id></element-citation></ref><ref id="B9-jcm-13-07074"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyldgaard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ellingsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hilberg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bendstrup</surname><given-names>E.</given-names></name></person-group><article-title>Rheumatoid arthritis-associated interstitial lung disease: Clinical characteristics and predictors of mortality</article-title><source>Respiration</source><year>2019</year><volume>98</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1159/000502551</pub-id><pub-id pub-id-type="pmid">31597131</pub-id></element-citation></ref><ref id="B10-jcm-13-07074"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spagnolo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Distler</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ryerson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Tzouvelekis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Bonella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bouros</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hiffman-Vold</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Crestani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name></person-group><article-title>Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)</article-title><source>Ann. Rheum. Dis.</source><year>2021</year><volume>80</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217230</pub-id><pub-id pub-id-type="pmid">33037004</pub-id><pub-id pub-id-type="pmcid">PMC7815631</pub-id></element-citation></ref><ref id="B11-jcm-13-07074"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Patnaik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schlenker-Herceg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hoffmann-Vold</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name></person-group><article-title>Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey</article-title><source>Adv. Ther.</source><year>2021</year><volume>38</volume><fpage>854</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1007/s12325-020-01578-6</pub-id><pub-id pub-id-type="pmid">33315170</pub-id><pub-id pub-id-type="pmcid">PMC7889674</pub-id></element-citation></ref><ref id="B12-jcm-13-07074"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijsenbeek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name></person-group><article-title>Spectrum of Fibrotic Lung Diseases</article-title><source>New Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>958</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2005230</pub-id><pub-id pub-id-type="pmid">32877584</pub-id></element-citation></ref><ref id="B13-jcm-13-07074"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Abril</surname><given-names>A.</given-names></name><name name-style="western"><surname>Distler</surname><given-names>J.H.</given-names></name></person-group><article-title>The role of antifibrotics in the treatment of rheumatoid arthritis&#8211;associated interstitial lung disease</article-title><source>Ther. Adv. Musculoskelet. Dis.</source><year>2022</year><volume>14</volume><fpage>1759720X221074457</fpage><pub-id pub-id-type="doi">10.1177/1759720X221074457</pub-id><pub-id pub-id-type="pmid">35186127</pub-id><pub-id pub-id-type="pmcid">PMC8852164</pub-id></element-citation></ref><ref id="B14-jcm-13-07074"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flaherty</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stowasser</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nintedanib in Progressive Fibrosing Interstitial Lung Diseases</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1718</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1908681</pub-id><pub-id pub-id-type="pmid">31566307</pub-id></element-citation></ref><ref id="B15-jcm-13-07074"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Distler</surname><given-names>J.H.W.</given-names></name><name name-style="western"><surname>Hoffmann-Vold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seibold</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mittoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dellaripa</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Aringer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>J.</given-names></name><name name-style="western"><surname>Distler</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Nintedanib in Patients with Autoimmune Disease&#8211;Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial</article-title><source>Arthritis Rheumatol.</source><year>2022</year><volume>74</volume><fpage>1039</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1002/art.42075</pub-id><pub-id pub-id-type="pmid">35199968</pub-id><pub-id pub-id-type="pmcid">PMC9321107</pub-id></element-citation></ref><ref id="B16-jcm-13-07074"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Aringer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burmester</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moros</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>M.</given-names></name></person-group><article-title>Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: Data from the INBUILD trial</article-title><source>Clin. Rheumatol.</source><year>2023</year><volume>42</volume><fpage>2311</fpage><lpage>2319</lpage><pub-id pub-id-type="doi">10.1007/s10067-023-06623-7</pub-id><pub-id pub-id-type="pmid">37209188</pub-id><pub-id pub-id-type="pmcid">PMC10412475</pub-id></element-citation></ref><ref id="B17-jcm-13-07074"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Danoff</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Woodhead</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Glaspole</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dellaripa</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Gooptu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vassallo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>P.G.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomized, double-blind, placebo-controlled, phase 2 study</article-title><source>Lancet Respir. Med.</source><year>2023</year><volume>11</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(22)00260-0</pub-id><pub-id pub-id-type="pmid">36075242</pub-id></element-citation></ref><ref id="B18-jcm-13-07074"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Bolster</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Danoff</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>George</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guyatt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>R.</given-names></name><etal/></person-group><article-title>2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases</article-title><source>Arthritis Rheumatol.</source><year>2024</year><volume>76</volume><fpage>1182</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1002/art.42861</pub-id><pub-id pub-id-type="pmid">38978310</pub-id></element-citation></ref><ref id="B19-jcm-13-07074"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narv&#225;ez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ca&#241;adillas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Castellv&#237;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Vincens-Zygmunt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bermudo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vidal-Montal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Nolla</surname><given-names>J.M.</given-names></name></person-group><article-title>Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome</article-title><source>Arthritis Res. Ther.</source><year>2024</year><volume>26</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s13075-024-03353-2</pub-id><pub-id pub-id-type="pmid">38890654</pub-id><pub-id pub-id-type="pmcid">PMC11184916</pub-id></element-citation></ref><ref id="B20-jcm-13-07074"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narv&#225;ez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lluch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Molina-Molina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vicens-Zygmunt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Luburich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ya&#241;ez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nolla</surname><given-names>J.M.</given-names></name></person-group><article-title>Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unrespon-sive to conventional immunosuppression</article-title><source>Semin. Arthritis Rheum.</source><year>2020</year><volume>50</volume><fpage>977</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2020.08.004</pub-id><pub-id pub-id-type="pmid">32911289</pub-id></element-citation></ref><ref id="B21-jcm-13-07074"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narv&#225;ez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Robles-P&#233;rez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Molina-Molina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vicens-Zygmunt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Luburich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ya&#241;ez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Nolla</surname><given-names>J.M.</given-names></name></person-group><article-title>Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease</article-title><source>Semin. Arthritis Rheum.</source><year>2020</year><volume>50</volume><fpage>902</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2020.08.008</pub-id><pub-id pub-id-type="pmid">32906025</pub-id></element-citation></ref><ref id="B22-jcm-13-07074"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kreuter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Altinisik</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonifazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Molyneaux</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>A Renzoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tomassetti</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>925</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30355-6</pub-id><pub-id pub-id-type="pmid">32890499</pub-id></element-citation></ref><ref id="B23-jcm-13-07074"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnett</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Edworthy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mcshane</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Fries</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Healey</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Luthra</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum.</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1002/art.1780310302</pub-id><pub-id pub-id-type="pmid">3358796</pub-id></element-citation></ref><ref id="B24-jcm-13-07074"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aletaha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neogi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Silman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Funovits</surname><given-names>J.</given-names></name><name name-style="western"><surname>Felson</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Bingham</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Birnbaum</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Burmester</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Bykerk</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.D.</given-names></name><etal/></person-group><article-title>2010 Rheumatoid artritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative</article-title><source>Arthritis Rheum.</source><year>2010</year><volume>62</volume><fpage>2569</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1002/art.27584</pub-id><pub-id pub-id-type="pmid">20872595</pub-id></element-citation></ref><ref id="B25-jcm-13-07074"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Thoracic Society</collab></person-group><article-title>European Respiratory Society. American Thoracic Society/European Respiratory Society interna-tional multidisciplinary consensus classification of the idiopathic interstitial pneumonias</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2002</year><volume>15</volume><fpage>277</fpage><lpage>304</lpage><comment><italic toggle="yes">Erratum in Am. J. Respir. Crit. Care Med.</italic>&#160;<bold>2002</bold>, <italic toggle="yes">166</italic>, 426</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/ajrccm.165.2.ats01</pub-id><pub-id pub-id-type="pmid">11790668</pub-id></element-citation></ref><ref id="B26-jcm-13-07074"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-R&#237;o</surname><given-names>F.</given-names></name><name name-style="western"><surname>Calle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgos</surname><given-names>F.</given-names></name><name name-style="western"><surname>Casan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Del Campo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Galdiz</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Giner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Mangado</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maestu</surname><given-names>L.P.</given-names></name><etal/></person-group><article-title>Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)</article-title><source>Arch Bronconeumol.</source><year>2013</year><volume>49</volume><fpage>388</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.arbres.2013.04.001</pub-id><pub-id pub-id-type="pmid">23726118</pub-id></element-citation></ref><ref id="B27-jcm-13-07074"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raghu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Collard</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Egan</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Behr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Colby</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Cordier</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Lasky</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and Management Committee on Idiopathic Pulmonary Fibrosis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2011</year><volume>15</volume><fpage>788</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1164/rccm.2009-040GL</pub-id><pub-id pub-id-type="pmcid">PMC5450933</pub-id><pub-id pub-id-type="pmid">21471066</pub-id></element-citation></ref><ref id="B28-jcm-13-07074"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raghu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rochwerg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cuello-Garcia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Behr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brozek</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Collard</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>W.</given-names></name><name name-style="western"><surname>Homma</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2015</year><volume>192</volume><fpage>e3</fpage><lpage>e19</lpage><pub-id pub-id-type="doi">10.1164/rccm.201506-1063ST</pub-id><pub-id pub-id-type="pmid">26177183</pub-id></element-citation></ref><ref id="B29-jcm-13-07074"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juge</surname><given-names>P.-A.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Vanni</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bade</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saavedra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dieud&#233;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dellaripa</surname><given-names>P.F.</given-names></name><etal/></person-group><article-title>Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease</article-title><source>Semin. Arthritis Rheum.</source><year>2023</year><volume>64</volume><fpage>152312</fpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2023.152312</pub-id><pub-id pub-id-type="pmid">38056314</pub-id><pub-id pub-id-type="pmcid">PMC10841613</pub-id></element-citation></ref><ref id="B30-jcm-13-07074"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duarte</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Marques Gomes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mazeda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abelha-Aleixo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>M.</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Meirinhos</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Antifibrotics in rheumatoid arthri-tis-associated interstitial lung disease - real-world data from a nationwide cohort</article-title><source>ARP Rheumatol.</source><year>2024</year><volume>3</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.63032/POPM9413</pub-id><pub-id pub-id-type="pmid">39368099</pub-id></element-citation></ref><ref id="B31-jcm-13-07074"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behera</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ganga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>K.</given-names></name></person-group><article-title>Antifibrotics in the Management of Rheumatoid Arthri-tis-Associated Interstitial Lung Disease: Prospective Real-World Experience from an Interstitial Lung Disease Clinic in India</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e63518</fpage><pub-id pub-id-type="pmid">39081417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.63518</pub-id><pub-id pub-id-type="pmcid">PMC11288335</pub-id></element-citation></ref><ref id="B32-jcm-13-07074"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ushio</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wakiya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kameda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miyagi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mizusaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chujo</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: A single-center study</article-title><source>BMC Rheumatol.</source><year>2024</year><volume>8</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s41927-024-00400-y</pub-id><pub-id pub-id-type="pmid">38886779</pub-id><pub-id pub-id-type="pmcid">PMC11184786</pub-id></element-citation></ref><ref id="B33-jcm-13-07074"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vacchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cerri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salvarani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Manfredi</surname><given-names>A.</given-names></name></person-group><article-title>Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: A new scenario is coming?</article-title><source>Respir. Med. Case Rep.</source><year>2020</year><volume>30</volume><fpage>101051</fpage><pub-id pub-id-type="doi">10.1016/j.rmcr.2020.101051</pub-id><pub-id pub-id-type="pmid">32292694</pub-id><pub-id pub-id-type="pmcid">PMC7150508</pub-id></element-citation></ref><ref id="B34-jcm-13-07074"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Manfredi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cassone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salvarani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cerri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>M.</given-names></name></person-group><article-title>Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease</article-title><source>Case Rep. Med.</source><year>2020</year><volume>2020</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1155/2020/6390749</pub-id><pub-id pub-id-type="pmid">32231705</pub-id><pub-id pub-id-type="pmcid">PMC7085352</pub-id></element-citation></ref><ref id="B35-jcm-13-07074"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mochizuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ikari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>K.</given-names></name></person-group><article-title>Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report</article-title><source>Mod. Rheumatol. Case Rep.</source><year>2023</year><volume>7</volume><fpage>350</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1093/mrcr/rxad021</pub-id><pub-id pub-id-type="pmid">37061836</pub-id></element-citation></ref><ref id="B36-jcm-13-07074"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narv&#225;ez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vicens-Zygmunt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Herrera-Lara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nolla</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Molina-Molina</surname><given-names>M.</given-names></name></person-group><article-title>Nintedanib for the treatment of refractory progressive rheumatoid arthritis&#8211;related interstitial lung disease: A real-life case series</article-title><source>Rheumatology</source><year>2020</year><volume>59</volume><fpage>3983</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keaa503</pub-id><pub-id pub-id-type="pmid">32940704</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-13-07074-f001" orientation="portrait"><label>Figure 1</label><caption><p>Evolution of the predicted forced vital capacity (%pFVC) and the predicted diffusing capacity for carbon monoxide corrected for hemoglobin (%pDLCO) before initiation of antifibrotic therapy and after 1 year of treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-13-07074-g001.jpg"/></fig><fig position="float" id="jcm-13-07074-f002" orientation="portrait"><label>Figure 2</label><caption><p>Lung function test results (as defined by the ATS) after 12 months of antifibrotic therapy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-13-07074-g002.jpg"/></fig><table-wrap position="float" id="jcm-13-07074-t001" orientation="portrait"><object-id pub-id-type="pii">jcm-13-07074-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of patients with RA-ILD at the initiation of initial antifibrotic medication.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Demographics and RA Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">N = 27</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age at age at initiation of antifibrotic treatment, years (mean &#177; SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 &#177; 10</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex, woman/man</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (44.5%)/15 (55.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body mass index (BMI), missing data = 4 (mean &#177; SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.3 &#177; 5.3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smoker or ex-smoker</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (67%) Current: 1 (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive rheumatoid factor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (85%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive ACPA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (81.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median duration of RA, months (IQR 25th&#8211;75th)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.5 (27.5&#8211;114)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DAS28-ESR at initiation of antifibrotic treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Remission or low activity</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (63%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;Moderate or high activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (37%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>ILD characteristics</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median duration of ILD, months (IQR 25th&#8211;75th)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (20&#8211;50)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HRCT pattern of ILD</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Usual interstitial pneumonia (definite or probable)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">21 (78%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Fibrotic non-specific interstitial pneumonia</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">5 (18%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Combined pulmonary fibrosis and emphysema</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%pFVC at initiation of initial antifibrotic medication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.6 &#177; 15</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%pDLCO at initiation of initial antifibrotic medication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.3 &#177; 14.8</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>Prior treatments</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Glucocorticoids</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (96%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean dose (&#177; SD), mg/day (IQR 25th&#8211;75th)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.3 &#177; 5.4 (5&#8211;10)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">csDMARDs or immunosuppressants *</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (81.5%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number of previous csDMARDs or immunosuppressants</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4 (minimum 1, maximum 2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Methotrexate</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">7 (26%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Leflunomide</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">18 (67%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Sulfasalazine</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">2 (8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Mycophenolate mofetil</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (8%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">bDMARD *</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (74%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number of previous bDMARD</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 (minimum 1, maximum 6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Rituximab</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">10 (37%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number of cycles</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4 (minimum 1, maximum 10)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Abatacept</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">11 (41%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">TNFi</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">4 (15%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Tocilizumab</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>Antifibrotic medication</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nintedanib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (92%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pirfenidone</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As initial antifibrotic medication/After nintedanib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (8%)/5 (18.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
<bold>Concomitant medication</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Glucocorticoids</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (93%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose of prednisone at initiation of initial antifibrotic medication,<break/>(mean &#177; SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.9 &#177; 5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">csDMARDs or immunosuppressants</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (78%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Leflunomide</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">16 (59%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Mycophenolate mofetil</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">4 (15%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">bDMARD or JAKi *</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (81.5%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Abatacept</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">13 (48%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">Rituximab</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">10 (37%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;<italic toggle="yes">TNFi</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">1 (4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;<italic toggle="yes">JAKi</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Need for oxygen therapy at initiation of initial antifibrotic medication</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">7 (26%)</td></tr></tbody></table><table-wrap-foot><fn><p>* Some patients received more than one. Abbreviations ACPA: anticitrullinated protein autoantibodies; bDMARD: biologic disease-modifying antirheumatic drugs; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; DAS28-ESR: Disease Activity Score in 28 joints using Erythrocyte Sedimentation Rate; HRCT: high-resolution computed tomography; ILD: interstitial lung disease; IQR: interquartile range; JAKi: Janus kinase inhibitors; %pDLCO: percent predicted diffusing capacity for carbon monoxide corrected for hemoglobin; %pFVC: percent predicted forced vital capacity; RA: rheumatoid arthritis; SD: standard deviation; TNFi: tumor necrosis factor inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-07074-t002" orientation="portrait"><object-id pub-id-type="pii">jcm-13-07074-t002_Table 2</object-id><label>Table 2</label><caption><p>Changes before and after 6 months and after 1 and 2 years of treatment with antifibrotic medication.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1">Before Antifibrotics</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At Time of RA-ILD Diagnosis<break/>Mean &#177; SD <break/>(IQR, 25th&#8211;75th)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At Time of Initiation of Initial Antifibrotic Medication<break/>Mean &#177; SD <break/>(IQR, 25th&#8211;75th)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta<break/>(Mean)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value<break/>(95% CI)</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Total sample (N = 27)</th><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" rowspan="1" colspan="1">95.5 &#177; 14.6 (88.1&#8211;107.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">86.6 &#177; 15 (73&#8211;97.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;8.9%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001 (7.81 to 16.02)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.1 &#177; 18.8 (55.4&#8211;79.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.3 &#177; 14.8 (44&#8211;66)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;14.8%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0001 (9.53 to 20.16)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1">
<bold>After 6 months of treatment</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>At time of</bold>
<bold>initiation of initial antifibrotic medication</bold>
<break/>
<bold>mean &#177; SD</bold>
<break/>
<bold>(IQR, 25th</bold>
<bold>&#8211;75th)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6 months post-treatment</bold>
<break/>
<bold>mean &#177; SD</bold>
<break/>
<bold>(IQR, 25th</bold>
<bold>&#8211;75th)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Delta</bold>
<break/>
<bold>(mean)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic toggle="yes">p</italic> value</bold>
<break/>
<bold>(95% CI)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Total sample (N = 24)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UIP: 21/Non-UIP: 3</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" rowspan="1" colspan="1">88.2 &#177; 19 (73.7&#8211;102.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">89.4 &#177; 22.7 (74.4&#8211;105.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">+1.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.611 (&#8722;5.67 to 3.41)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.4 &#177; 16.6 (46.2&#8211;68.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.3 &#177; 24.9 (40.5&#8211;79.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+3.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.400 (&#8722;13.51 to 5.63)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1">
<bold>After 1 year of treatment</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>At time of</bold>
<bold>initiation of initial antifibrotic medication</bold>
<break/>
<bold>mean &#177; SD</bold>
<break/>
<bold>(IQR, 25th</bold>
<bold>&#8211;75th)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>12 months post-treatment</bold>
<break/>
<bold>mean &#177; SD</bold>
<break/>
<bold>(IQR, 25th</bold>
<bold>&#8211;75th)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Delta</bold>
<break/>
<bold>(mean)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic toggle="yes">p</italic> value</bold>
<break/>
<bold>(95% CI)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Total sample (N = 18)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UIP: 15/NSIP: 3</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" rowspan="1" colspan="1">87.5 &#177; 20.7 (71.8&#8211;108.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">92.2 &#177; 24.8 (76&#8211;115.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">+4.7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023 (&#8722;8.66 to 0.74)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.2 &#177; 17.9 (45.7&#8211;69.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.4 &#177; 16.7 (42.7&#8211;67)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;3.8%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.175 (&#8722;1.82 to &#8722;9.25)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1">
<bold>After 2 years of treatment</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>At time of</bold>
<bold>initiation of initial antifibrotic medication</bold>
<break/>
<bold>mean &#177; SD (IQR, 25th&#8211;75th)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>24 months post-treatment</bold>
<break/>
<bold>mean &#177; SD (IQR, 25th&#8211;75th)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Delta</bold>
<break/>
<bold>(mean)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic toggle="yes">p</italic> value</bold>
<break/>
<bold>(95% CI)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Total sample (N = 9)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UIP: 7/NSIP: 2</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" rowspan="1" colspan="1">89.1 &#177; 19.7 (71.6&#8211;111.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">97.4 &#177; 19.7 (84.3&#8211;120.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">+7.7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037 (&#8722;16.07 to 0.66)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.8 &#177; 20.3 (43.8&#8211;81.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.6 &#177; 15.1 (45.5&#8211;73.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.2%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.621 (&#8722;7.67 to &#8722;12.07)</td></tr></tbody></table><table-wrap-foot><fn><p>%pFVC = predicted forced vital capacity; %pDLCO = predicted diffusing capacity for carbon monoxide, corrected for hemoglobin; UIP: usual interstitial pneumonia and NSIP: fibrotic non-specific interstitial pneumonia.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-07074-t003" orientation="portrait"><object-id pub-id-type="pii">jcm-13-07074-t003_Table 3</object-id><label>Table 3</label><caption><p>Lung function test results according to the definitions of ATS after antifibrotic therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">After 6 Months of Treatment<break/>N = 24</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improvement</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stabilization</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Worsening</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5% (3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75% (18)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5% (3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21% (5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58% (14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21% (5)</td></tr><tr><td colspan="4" align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1">After 12 months of treatment<break/>N = 18</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.2% (4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.7% (12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.1% (2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.1% (2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.2% (11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.7% (5)</td></tr><tr><td colspan="4" align="left" valign="middle" style="border-bottom:solid thin;background:#F2F2F2" rowspan="1">After 24 months of treatment<break/>N = 9</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%FVC predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.5% (4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.5% (5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%DLCO predicted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.2% (2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.5% (4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.3% (3)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jcm-13-07074-t004" orientation="portrait"><object-id pub-id-type="pii">jcm-13-07074-t004_Table 4</object-id><label>Table 4</label><caption><p>Adverse events associated with antifibrotic therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N = 27</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any adverse event</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (81.5%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Most frequent adverse events</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (63%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nausea/Vomiting</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (33%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALT o AST increased</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (26%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Decreased appetite/weight loss</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (37%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Asthenia</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (7.4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdominal pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (11%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Adverse event leading to permanent dose reduction</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nintedanib (N = 25)/Pirfenidone (N = 7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (40%)/1 (14%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Adverse event leading to treatment discontinuation</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (18.5%)</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>